---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: FORTIFI-FLEX"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: FORTIFI-FLEX. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 32 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence/fortifi-flex"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: FORTIFI-FLEX

<a id="heading-3.1.3"></a>

## 3.1.3 FORTIFI-FLEX

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Study aim in the ClinicalTrials.gov record

> “The study aims to demonstrate that the antitumor activity of an alternative dosing regimen of ficerafusp alfa in combination with pembrolizumab is comparable to the weekly ficerafusp alfa regimen in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.1-2"></a>

#### Main and secondary objectives in the EU trial record

> “To evaluate whether the antitumor activity of the once every 3 weeks (Q3W) alternative ficerafusp alfa dosing regimen is maintained when compared to the standard weekly dosing regimen after randomization”
> “To evaluate the pharmacokinetics of ficerafusp alfa”
> “To further evaluate antitumor activity during the maintenance phase for participants receiving the alternative and standard dosing regimens”
> “To evaluate antitumor activity for the overall dosing regimen across the full study treatment course, including both loading and maintenance phases”
> “To evaluate the safety and tolerability profile during the maintenance phase for participants receiving the alternative and standard maintenance dosing regimens”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.1-3"></a>

#### Study purpose in the quarterly report

> “We expect to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Study start (estimated) | “2026-09” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2029-03” |
| First posted | “2026-09-08” |
| Sites | “This study has 7 locations” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.2-2"></a>

#### Study initiation in the quarterly report

> “In August 2026, we announced the initiation of FORTIFI-FLEX, a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg QW followed by maintenance dosing of 2250mg every three weeks as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Open-label randomized phase 2 design in the ClinicalTrials.gov record

> “A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma”
> “Participants who remain on study without progression at the end of the loading phase will enter the maintenance phase and will be randomized 2:1 to one of the following arms:”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.3-2"></a>

#### Study design in the second-quarter results press release

> “Initiated FORTIFI-FLEX, a randomized, open-label, clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W).”

Source: [Bicara Therapeutics second quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)

<a id="topic-3.1.3.3-3"></a>

#### Study schema in the corporate presentation

> “Loading phase”
> “Maintenance phase”
> “FICERA 2250mg Q3W”
> “1L R/M HPV-negative HNSCC”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Age ≥18 years on the day the Informed Consent Form is signed.”
> “Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.”
> “No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.”
> “Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.”
> “PD-L1 CPS ≥1.”
> “Measurable disease based on RECIST 1.1.”
> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Adequate organ function, as defined in the protocol.”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Disease suitable for local therapy administered with curative intent.”
> “Prior treatment with anti-TGFβ therapy.”
> “Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).”
> “Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.”
> “Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.”
> “Life expectancy less than 3 months.”
> “Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.”
> “Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.”
> “Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.”
> “Active autoimmune disease requiring systemic treatment in the past 2 years.”
> “Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.”
> “Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.”
> “Known history of human immunodeficiency virus (HIV).”
> “Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.”
> “Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.”
> “Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.”
> “Use of a live or live attenuated vaccine within 4 weeks prior to Screening.”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.4-3"></a>

#### HPV status determination in the EU trial record

> “Participant has histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx, or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: Primary tumor locations of paranasal sinuses and nasopharynx or tumor of any other histology are excluded.”
> “Participants presenting with primary tumor location in oropharynx must have documentation of HPV-negative disease as determined by a validated test.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.4-4"></a>

#### PD-L1 assay and testing in the EU trial record

> “Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (by PD-L1 immunohistochemistry [IHC] 22C3), determined locally or centrally.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.4-5"></a>

#### Prior-therapy criteria in the EU trial record

> “No prior systemic therapy administered in the R  or M setting. Systemic therapy completed >6 months prior to signing ICF if given as part of multimodal treatment for locoregionally advanced disease is allowed.”
> “Prior therapy with an anti-EGFR antibody”
> “Prior (neoadjuvant and/or adjuvant) therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “PD (radiologically or pathologically confirmed) <6 months from completion of curative intent platinum-containing systemic therapy for locoregionally advanced HNSCC.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.4-6"></a>

#### Measurable disease and performance status in the EU trial record

> “Participant has measurable disease based on RECIST 1.1 as determined by BICR.”
> “Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Treatment arms in the ClinicalTrials.gov record

| Arm | Quoted regimen |
| --- | --- |
| Arm A, loading phase | “Loading phase (12 weeks): Ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” |
| Arm A, maintenance phase | “Maintenance phase: Ficerafusp alfa 2250 mg Q3W (alternative dose) + pembrolizumab 200 mg Q3W.” |
| Arm B | “Continuous ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.5-2"></a>

#### Loading regimen for all participants in the ClinicalTrials.gov record

> “All participants will receive ficerafusp alfa 1500 mg once weekly (QW in combination with pembrolizumab 200 mg every three weeks (Q3W) for 12 weeks (loading phase).”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Progression-free Survival Rate in the Maintenance Phase as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoint in the ClinicalTrials.gov record

| Primary endpoint | Quoted record |
| --- | --- |
| Measure | “Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.” |
| Time frame | “Approximately 9 months.” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.6.1-2"></a>

##### Primary endpoint in the EU trial record

> “Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors 1.1 and alive after randomization”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.6.1-3"></a>

##### Secondary endpoints in the ClinicalTrials.gov record

> “Serum exposure of ficerafusp alfa.”
> “Objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR).”
> “Disease control rate (DCR) per RECIST 1.1 by blinded independent central review (BICR)”
> “Clinical Benefit Rate (CBR) per RECIST 1.1 by blinded independent central review (BICR)”
> “Duration of Response (DOR) per RECIST 1.1 by blinded independent central review (BICR).”
> “Progression-free survival (PFS) per RECIST 1.1 by blinded independent central review (BICR).”
> “Overall Survival (OS)”
> “Time to Response (TTR) per RECIST 1.1 by blinded independent central review (BICR)”
> “Deep Response Rate by blinded independent central review (BICR)”
> “Time to maximum tumor shrinkage”
> “Incidence of ≥Grade 3 TEAEs”
> “Incidence of Serious adverse events (SAEs)”
> “Incidence of Adverse events (AEs) leading to dose modifications (dose reduction, interruption, dose held, or discontinuation)”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.6.1-4"></a>

##### Deep response definition in the EU trial record

> “Deep response rate among responders (defined as best target lesion shrinkage ≥80%)”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.6.1-5"></a>

##### Regulatory basis for the alternate regimen in company documents

> “Based on recent discussions with the U.S. Food and Drug Administration (FDA), the company plans to initiate a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W).”

Source: [Bicara Therapeutics first quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-first-quarter-2026-financial-results)

> “The primary endpoint will evaluate the proportion of patients in the maintenance phase who are progression-free.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-3.1.3.6.1-6"></a>

##### Basis in the every-two-week expansion cohort in the annual report

> “The purpose of this expansion cohort was to further support the pharmacokinetic and pharmacodynamic profile of ficerafusp alfa, particularly its eight-day half-life, and the development of a less frequent dose regimen.”
> “In conjunction with the presentation of those data, we announced plans to develop ficerafusp alfa with a loading and every-three-week maintenance schedule and aim to achieve regulatory alignment to enable data generation by potential U.S. approval.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.3.6.1-7"></a>

##### FDA dose-optimization guidance on activity endpoints for dosage comparisons

> “Relevant measures of activity may include tumor assessment-based endpoints (e.g., overall response rate: ORR, progression-free survival: PFS), and other tissue, blood, or imaging-based endpoints.”
> “The trial should be sized to allow for sufficient assessment of safety and antitumor activity for each dosage.”

Source: [FDA (2024)](https://www.fda.gov/media/164555/download)

<a id="topic-3.1.3.6.1-8"></a>

##### FDA endpoint guidance on progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 160”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.7.1-2"></a>

##### Planned enrollment in the corporate presentation

> “(n=150-200)”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Maintenance-phase randomization in the ClinicalTrials.gov record

> “Participants who remain on study without progression at the end of the loading phase will enter the maintenance phase and will be randomized 2:1 to one of the following arms:”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.7.2-2"></a>

##### Maintenance-phase and overall-course analyses in the EU trial record

> “To further evaluate antitumor activity during the maintenance phase for participants receiving the alternative and standard dosing regimens”
> “To evaluate antitumor activity for the overall dosing regimen across the full study treatment course, including both loading and maintenance phases”
> “To evaluate the safety and tolerability profile for the overall dosing regimen across the full study treatment course, including both loading and maintenance phase”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Enrollment status in the third-quarter results press release

> “Continue to enroll FORTIFI-FLEX, a randomized, open-label clinical trial that is evaluating ficerafusp alfa, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W) as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

FORTIFI-FLEX is open-label, with no masking. Randomization occurs only after the 12-week loading phase and includes only participants without progression, so the randomized comparison addresses maintenance dosing in that subset. Both arms receive ficerafusp alfa with pembrolizumab. The primary endpoint, the proportion of maintenance-phase participants alive and progression-free at approximately 9 months, is assessed by BICR. Planned enrollment is 160 participants, and no results have been reported.

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163); [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.9-2"></a>

#### Open-label design in the EU trial record

> “Multicenter, open-label, randomized Phase 2 study evaluating continuous weekly dosing of ficerafusp alfa (BCA101) in combination with pembrolizumab versus an alternative dosing regimen for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.9-3"></a>

#### Masking in the ClinicalTrials.gov record

> “Masking : None (Open Label)”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
